Sea Pharm

SeaPharm was a pioneering marine biotechnology company founded in 1983, dedicated to the discovery and development of pharmaceutical compounds derived from marine organisms. Headquartered in Fort Pierce, Florida, the company utilized deep-sea submersibles to collect rare marine specimens for high-throughput drug screening, primarily targeting oncology. Its research led to the identification of several potent anti-tumor agents, most notably discodermolide and bryostatin 1, which advanced into clinical trials. The company established a landmark $100 million research partnership with SmithKline Beecham to commercialize its marine-derived pipeline. Although SeaPharm eventually dissolved and its assets reverted to partners or research institutions, its work laid the foundational framework for modern marine pharmacology and natural product drug discovery.